Actively Recruiting
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Led by EyebioKorea, Inc. · Updated on 2024-08-27
50
Participants Needed
5
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients with Neovascular Age-related Macular Degeneration. The purpose of this study is to primarily investigate the safety and tolerability of EB-203 by dose in patients with neovascular Age-related Macular Degeneration (nAMD), and to secondarily evaluate the clinical efficacy. Subject to Adults aged 50 years or older and Neovascular age-related macular degeneration (nAMD)
CONDITIONS
Official Title
Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 50 years or older
- Best corrected visual acuity (BCVA) score between 25 and 73 on the ETDRS chart at 4 meters (equivalent to 20/40 to 20/320 Snellen)
- Voluntarily signed informed consent after receiving study information
You will not qualify if you...
- Confirmed nAMD requiring standard treatment in both eyes (dry AMD in non-study eye allowed)
- Prior ocular or systemic treatment for nAMD such as photodynamic therapy or laser photocoagulation, or surgery (excluding health supplements)
- Previous anti-VEGF drug or combination therapy in the study eye before screening
- Prior intravitreal steroid treatment
- Subretinal hemorrhage covering 50% or more of lesion area or hemorrhage in subfoveal region larger than or equal to 1 optic disk area in study eye
- Vitreous hemorrhage in study eye
- Previous vitrectomy
- History of retinal detachment or related congenital disease or surgery
- Scarring, fibrosis, or atrophy involving the center of the fovea in study eye
- Choroidal neovascularization in study eye due to causes other than nAMD (except polypoidal choroidal vasculopathy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Busan Paik Hospital, Inje University
Busan, South Korea, 47392
Actively Recruiting
2
Pusan National University Hospital
Busan, South Korea, 49241
Actively Recruiting
3
Yeungnam University Medical Center
Daegu, South Korea, 42415
Actively Recruiting
4
Kim's Eye Hospital
Seoul, South Korea, 08858
Actively Recruiting
5
Seoul National University Hospital
Seoul, South Korea, 08858
Actively Recruiting
Research Team
S
SUYEON KIM
CONTACT
Y
YUNSEOK CHO
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here